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Abstract
Hepatocellular carcinoma (HCC) affects more than half a million people worldwide and is the
third most common cause of cancer deaths. Because mammalian target of rapamycin (mTOR)
signaling is up-regulated in 50% of HCCs, we compared the effects of the U.S. Food and Drug
Administration–approved mTOR-allosteric inhibitor, RAD001, with a new-generation
phosphatidylinositol 3-kinase/mTOR adenosine triphosphate–site competitive inhibitor, BEZ235.
Unexpectedly, the two drugs acted synergistically in inhibiting the proliferation of cultured HCC
cells. The synergistic effect closely paralleled eukaryotic initiation factor 4E-binding protein 1
(4E-BP1) dephosphorylation, which is implicated in the suppression of tumor cell proliferation. In
a mouse model approximating human HCC, the drugs in combination, but not singly, induced a
marked regression in tumor burden. However, in the tumor, BEZ235 alone was as effective as the
combination in inhibiting 4E-BP1 phosphorylation, which suggests that additional target(s) may
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also be involved. Microarray analyses revealed a large number of genes that reverted to normal
liver tissue expression in mice treated with both drugs, but not either drug alone. These analyses
also revealed the down-regulation of autophagy genes in tumors compared to normal liver.
Moreover, in HCC patients, altered expression of autophagy genes was associated with poor
prognosis. Consistent with these findings, the drug combination had a profound effect on UNC51-
like kinase 1 (ULK1) dephosphorylation and autophagy in culture, independent of 4E-BP1, and in
parallel induced tumor mitophagy, a tumor suppressor process in liver. These observations have
led to an investigator-initiated phase 1B-2 dose escalation trial with RAD001 combined with
BEZ235 in patients with HCC and other advanced solid tumors.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer and—because of
late diagnosis, poor treatment options, and aggressive disease—ranks third in cancer deaths
(1). Most patients present with intermediate- or advanced-stage disease, and surgical
resection is an option for less than 20% of these patients (2). Although the number of HCC
cases in North America is relatively small, it is the most rapidly expanding tumor type (3, 4).
Two-thirds of these cases are attributed to chronic alcohol use, exposure to toxic agents, or
prolonged hepatitis B or C infection (5); however, the remaining third have been linked to
nonalcoholic steatohepatitis, most likely driven by the recent epidemic in obesity.
Currently, sorafenib, a multiprotein kinase inhibitor, shows unprecedented clinical response
in HCC patients (6, 7). However, the response is not enduring, underscoring the need for
novel therapies. One candidate target that has emerged is the mammalian target of
rapamycin (mTOR) signaling pathway, which is hyperactivated in 40 to 50% of HCC cases.
Moreover, recent studies have shown that HCC incidence and progression are significantly
augmented by a high-fat diet (8), which is known to lead to an increase in circulating
branched-chain amino acids (BCAAs) and induction of mTOR signaling independent of
phosphatidylinositol 3-kinase (PI3K) signaling (9, 10). On the basis of these observations,
rapamycin and two derivatives, everolimus (RAD001) and temsirolimus (CCI-779), are
under evaluation in phase 1, 1–2, 2, 2–3, and 3 clinical trials for the treatment of HCC (11).
mTOR can be found in two multiprotein kinase complexes: mTORC1 and mTORC2. Both
complexes contain mLST8 and a number of distinct interacting proteins, including raptor
and rictor, which define mTORC1 and mTORC2, respectively. Although both complexes
respond to hormones and mitogens, only mTORC1 responds to nutrients, including BCAAs,
and cellular energy inputs (9). Mitogens initiate mTORC1 signaling by the canonical PI3K/
protein kinase B (PKB/Akt) pathway (12, 13). The most studied effectors downstream of
mTORC1 are the ribosomal protein S6 kinases (S6K1/2) and the eukaryotic protein
synthesis initiation factor 4E-binding proteins (4E-BP1/2). mTORC2 mediates activation of
PKB/Akt and serum/glucocorticoidregulated kinase 1. The mTOR complexes are key
regulators of multiple cellular processes including translation, growth, proliferation,
metabolism, and autophagy (14, 15).
The rapamycins form a complex with the immunophilin FKBP12, which binds to an
allosteric site near the kinase domain to inhibit mTOR signaling. Mutation of a single
residue in the rapamycin- FKBP12 binding site confers complete resistance (16). Although
the rapamycins are used clinically, they potentiate PI3K activation through inhibition of the
mTORC1/S6K1 negative feedback loop (17, 18) and incompletely suppress mTORC1
signaling to 4E-BP1 (19). Therefore, we chose an mTOR adenosine triphosphate (ATP)–site
competitive inhibitor to test efficacy in the treatment of HCC. We made the unexpected
observation that RAD001 and BEZ235 synergized at low doses on mTORC1 and mTORC2,
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causing tumor regression in mouse models best approximating human HCC (20, 21).
Moreover, this effect was associated with a marked increase in autophagy, which correlated
with UNC51-like kinase 1 (ULK1) dephosphorylation in cell culture, independent of S6K1
or 4E-BP1.
RESULTS
RAD001 and BEZ235 synergistically inhibit mTOR signaling in HCC cells
Treatment of the human HCC cell line Huh7 with 5 nM RAD001abolished S6K1 activation,
as measured by S6K1 Thr389 (T389) and S6 Ser240/Ser244 (S240/244) phosphorylation (Fig.
1A). This treatment was associated with an approximate threefold increase in PKB/Akt S473
phosphorylation because of suppression of the mTORC1/S6K1 negative feedback loop (18)
(Fig. 1A). RAD001 had some effect on 4E-BP1 T37/46 but virtually no effect on S65
phosphorylation (Fig. 1A). BEZ235 treatment also led to inhibition of S6K1 T389
phosphorylation and an approximate threefold potentiation of PKB/Akt S473
phosphorylation, consistent with mTORC1/S6K1 inhibition (Fig. 1A). However, at doses of
100 nM BEZ235, mTORC2 began to be inhibited, as evidenced by PKB/Akt S473
dephosphorylation. Unlike RAD001, BEZ235 caused both S6K1 and 4E-BP1
dephosphorylation (Fig. 1A). These data suggest that low BEZ235 concentrations
selectively inhibit mTORC1 and the negative feedback loop, but higher BEZ235
concentrations inhibit both mTORC1 and mTORC2.
To test the effect of the two drugs together, we kept the RAD001 concentration at 5 nM and
gradually increased the BEZ235 concentration. Unexpectedly, at 5 nM BEZ235,
phosphorylation of 4E-BP1 S65 and T37/46 was largely abolished in the presence of
RAD001 (Fig. 1B), an effect requiring 50 nM BEZ235 when used alone (Fig. 1A).
Moreover, the potentiation of PKB/Akt S473 phosphorylation was blunted at 50 nM BEZ235
in combination with 5 nM RAD001, whereas this was not observed when BEZ235 was used
alone at 50 nM (compare Fig. 1, A and B). These findings indicate that the two drugs act
synergistically to inhibit both mTORC1 and mTORC2 signaling. Next, we determined
whether the effects of drug treatment on cell proliferation more closely followed 4E-BP1 or
PKB/Akt dephosphorylation. RAD001 alone at all concentrations tested inhibited cell
proliferation by about 50%, whereas BEZ235 caused a dose-dependent inhibition of
proliferation, reaching a maximum at 100 nM (Fig. 1C). In combination, proliferation was
almost completely abolished at the lowest concentration of each drug, 5 nM (Fig. 1C). Using
the Chou-Talalay equation (22), we achieved synergy at 5 nM RAD001 with either 5 or 10
nm BEZ235 (table S1), with inhibition of proliferation closely paralleled by 4E-BP1
dephosphorylation (Fig. 1B). The parallel effects on 4E-BP1 dephosphorylation and cell
proliferation are not cell line–dependent, because synergy was also observed in the human
HCC Alexander cell line and mouse HCC cell lines derived from either a primary
diethylnitrosamine (DEN)–induced tumor (8) or a transgenic E2F1-induced tumor (23),
although at different concentrations (fig. S1, A to C). These observations suggest that the
effects of RAD001 in combination with BEZ235 more closely follow the inhibition of
mTORC1 than mTORC2, on the basis of 4E-BP1 phosphorylation compared to that of PKB/
Akt.
RAD001 and BEZ235 synergistically inhibit the in vitrokinase activity of mTORC1 and
mTORC2
To determine whether the synergistic effects of RAD001 and BEZ235 were elicited at the
level of mTOR, we tested the drugs in an mTORC1 in vitro kinase assay, after
immunoprecipitation with a raptor antibody and using 4E-BP1 as a substrate (24). The
phosphorylation of 4E-BP1 T37/46 was not significantly inhibited by 20 nM RAD001, in
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contrast to increasing concentrations of BEZ235 from 50 to 250 nM (Fig. 2A). Critically, the
combination of 20 nM RAD001 and 250 nM BEZ235 resulted in synergistic inhibition of
mTORC1 activity compared to inhibition with the same concentration of either drug alone
(Fig. 2A). The ability of RAD001 to sensitize PKB/Akt S473 to BEZ235-induced
dephosphorylation in Huh7 cells can be attributed to the loss of the negative feedback loop
from mTORC1/S6K1 to PKB/Akt. However, these effects may also result from the binding
of RAD001/FKBP12 to mTORC2 (25). We found that BEZ235 inhibited mTORC2
phosphorylation of PKB/Akt in vitro, and this effect was enhanced by RAD001 (Fig. 2B),
suggesting that the observed synergy is through inhibition of mTORC2, not through other
targets.
RAD001 and BEZ235 act synergistically to inhibit HCC progression
Primary events leading to human HCC are best represented in mouse models initiated by
injury, resulting in compensatory proliferation of liver cells (20, 21, 26). To address this
issue, we used the DEN-induced HCC model (27), whose gene expression profile
corresponds closely to that of human HCC with unfavorable outcome (20, 21). C57BL/6
mice treated with DEN at 2 weeks exhibited tumors (fig. S2A) between 1.05 and 2618 mm3
at ~44 weeks, as measured by magnetic resonance imaging (MRI) (Fig. 3A). Tumor-bearing
mice were divided into four treatment arms on the basis of tumor burden (Fig. 3A) and
gavaged daily for 28 days with the recommended doses (Novartis Oncology) of RAD001
(10 mg/kg), BEZ235 (30 mg/kg), or a combination of RAD001 (2.5 mg/kg) and BEZ235 (18
mg/kg). Such treatment had no apparent effect on body weight throughout the course of the
experiment (fig. S2B). Similarly, treatment with either drug alone or in combination had no
adverse effects on body weight of transgenic mice engineered to ectopically express E2F1/c-
Myc in the liver (fig. S4A), a mouse model of human HCC, with better prognosis (20).
On the basis of MRI analyses, tumor volumes of placebo-treated mice doubled on average
within the 28 days of the study, whereas treatment with either RAD001 or BEZ235 alone
had a pronounced inhibitory effect on this response (Fig. 3, A and B). More striking, the
lower doses of the drug combination induced a marked effect in HCC regression, relative to
mice treated with either drug alone at optimal doses (Fig. 3, A and B). This was particularly
evident by comparing the ratio of liver weight to body weight (fig. S2C). The reduction in
HCC progression in the combined treatment could be accounted for, in part, by the
cumulative effect of an increase in apoptosis (fig. S2D) and a decrease in proliferation, as
determined by quantitative immunohistochemistry (IHC) of Ki67-stained tumor sections
(Fig. 3, C and D). Similar results were obtained for HCCs of E2F1/c-Myc–treated mice (fig.
S4, B and C). Unexpectedly, in DEN-induced tumors, unlike cells in culture (Fig. 1), 4E-
BP1 T37/46 phosphorylation was inhibited to the same extent by BEZ235 alone as in
combination with RAD001 (Fig. 3, C and D, and fig. S3A), as confirmed by Western blot
analyses (fig. S3, B and C). Likewise, by Western blot analyses or IHC, dephosphorylation
of PKB/Akt S473 induced by BEZ235 alone was as potent as the drug combination (fig. S3,
B and D to F), suggesting that in addition to 4E-BP1 and PKB/Akt, other targets are
involved in the synergistic response in tumor regression.
RAD001 and BEZ235 cause reversal of gene expression levels in tumors
For deeper insights into the effects of differential drug treatments, DEN-induced tumors and
normal livers were profiled by gene expression microarrays at the end of the 28-day
treatment period. Four comparisons were made: placebo-treated liver versus placebo-treated
tumor, and placebo-treated tumor versus each of the drug regimens. Gene expression
analysis identified 5665 genes that were significantly altered (false discovery rate <0.25)
between placebo-treated livers and placebo-treated tumors, whereas 245, 146, and 708 genes
were significantly changed in placebo-treated tumors compared to tumors treated with
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RAD001, BEZ235, and BEZ235 plus RAD001, respectively. Of the genes significantly
affected in placebo-treated liver compared to placebo-treated tumor, 195, 115 and 475 genes
in tumors treated with RAD001, BEZ235, or RAD001 plus BEZ235, respectively, reverted
to roughly baseline expression levels of placebo-treated liver (Fig. 4A and table S2).
Assessment of the gene sets using the Fisher’s exact test revealed that a significant number
of cancer genes renormalized to placebo-treated liver (P < 2.2 × 10−16) in all three
treatment groups. Only 50% of the genes affected by RAD001 were also affected by
BEZ235, whereas the combined treatment affected 354 distinct genes, providing
confirmation of cooperative interaction between BEZ235 and RAD001 in vivo (Fig. 4A).
The ability of the RAD001/BEZ235 combination, compared with either agent alone, to
induce reversion to the gene expression phenotype of placebo-treated liver is depicted in the
heat map of the data (Fig. 4B). Gene Set Enrichment Analysis (GSEA) identified cell cycle
inhibition as one of the major pathways altered by the combination of both drugs, which was
not observed in the single-drug treatments (table S3). These data suggest that the interaction
of the two drugs in vivo is distinct from either alone.
RAD001 and BEZ235 synergize on autophagy
In the pairwise comparative microarray analyses, we noted changes in a number of
autophagy genes. Although a few were up-regulated in tumors, almost half were
significantly down-regulated (table S4), two of which, Atg5 and Atg7, are tumor suppressors
in liver (28, 29). Analysis of existing microarray data sets from HCC patients, having the
signature of A (poor prognosis) versus B (good prognosis) (20), showed that the altered
expression of autophagy genes is associated with those patients having a poor prognosis, as
shown in the Kaplan-Meier plot of these subsets of HCC patients (P < 0.01) (fig. S5).
Although BEZ235 and RAD001 stimulate autophagy (30), a role for autophagy in
suppressing DEN-induced HCC (Fig. 3) would not be consistent with reports thatautophagy
is mediated by 4E-BP1 (31, 32), because BEZ235 alone induces 4E-BP1 dephosphorylation
to almost the same extent as that of the drug combination (Fig. 3E).
Recent studies argue that mTORC1 can directly suppress autophagy by phosphorylating
autophagy-initiating kinase ULK1 at S757 (33). Thus, we asked whether RAD001 and
BEZ235 synergize on the autophagic response and ULK1 S757 dephosphorylation and
whether these effects were 4E-BP1/2–dependent. To measure autophagy and 4E-BP1/2
dependence, we took advantage of a glutathione S-transferase–tagged betaine homocysteine
methyltransferase (GST-BHMT) reporter, whose cleavage represents a cargo-based
autophagy end point (34), and human embryonic kidney (HEK) 293 cells stably expressing
either a nonsilencing short hairpin RNA (shRNA), (shNS) or an shRNA against 4E-BP1/2
(sh4E-BP1/2) (19). Withdrawal of aminoacids and serum from shNS cells led to
dephosphorylation of S6K1, 4E-BP1, and ULK1 (Fig. 5A), with similar results obtained for
S6K1 and ULK1 in sh4E-BP1/2 cells (Fig. 5B). However, basal levels of the GST-BHMT
fragment were indistinguishable in shNS versus sh4EBP1/2 cells, as was the extent of
fragment accumulation caused by serum and amino acid withdrawal (Fig. 5, A and B).
Treatment with 5 nM RAD001 induced S6K1 dephosphorylation but had little impact on
4E-BP1 and ULK1 phosphorylation or on the accumulation of the GST-BHMT fragment in
shNS cells (Fig. 5A), with equivalent results obtained for S6K1 and ULK1 in sh4E-BP1/2
cells (Fig. 5B). The combination of the two drugs had a synergistic effect on the
accumulation of the GST-BHMT fragment and ULK1 S757 dephosphorylation (Fig. 5, A
and B) independent of 4E-BP1/2 (Fig. 5B) and S6K1 (Fig. 5, A and B). Thus, the induction
of autophagy can occur independently of 4E-BP1/2 and S6K1.
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RAD001 and BEZ235 induce autophagy in liver tumors
The findings above raised the question of whether autophagy might more closely follow
regression of DEN-induced tumors than 4E-BP1 dephosphorylation (Fig. 3). To explore this,
we examined liver tumors for autophagosome formation by transmission electron
microscopy (TEM). The TEM images revealed double-membrane vesicles indicative of
autophagosomes, which were studded with small particles resembling ribosomes (Fig. 6A),
consistent with autophagosomes being derived from the endoplasmic reticulum (35, 36). By
morphometric analysis, many more autophagosome-like structures were detected in the
RAD001/BEZ235 combination compared to tumors treated with placebo or either drug
alone (Fig. 6, A and B). Mitochondria were the apparent target (Fig. 6A), consistent with the
induction of mitophagy in nutrient-deprived hepatocytes (37). Although tumor regression in
HCC tumors treated with a combination of RAD001 and BEZ235 may be due to multiple
factors, the data suggest that autophagy, specifically mitophagy, is a major effector.
DISCUSSION
We set out to determine whether BEZ235 would be a more effective inhibitor of HCC
progression than RAD001. Unexpectedly, the two in combination are more potent than
either agent alone in inhibiting proliferation of HCC cells in culture and tumors in vivo
(Figs.1 and 3). Consistent with earlier findings that rapamycin affects substrate specificity,
not kinase activity (38), recent studies show that the ability of the rapamycins to inhibit
mTORC1 signaling is more pronounced for S6K1 than 4E-BP1 (39, 40). This has led to the
suggestion that S6K1, but not 4E-BP1, is excluded from interacting with mTORC1 because
of its relative larger size (41, 42). However, S6K1 is about half the size of ULK1, whose
phosphorylation is largely unaffected by rapamycin. It is more likely that mTORC1 activity
is dependent on the conformation of a ternary complex that includes the kinase, the
substrate, and ATP. In contrast, the new mTOR ATP-binding site competitive drugs inhibit
both mTOR complexes and block 4E-BP1 phosphorylation to the same extent as S6K1 (39,
40, 43). Downstream of mTORC1, we recently showed that the main effects of these
inhibitors on cell proliferation are attributed to activation of the 4E-BPs (19). These findings
are consistent with our observations using RAD001 and BEZ235 in HCC cell lines (Fig. 1
and fig. S1); however, inhibition of 4E-BP1 alone is not sufficient to explain the effects on
HCC progression, which eventually led us to examine the role of autophagy.
It has been demonstrated that prolonged treatment with rapamycin affects mTORC2, in
addition to mTORC1 (44). This response is more difficult to discern, because rapamycin
also relieves the negative feedback loop from mTORC1/S6K1 to PKB/Akt (Fig. 1A). A
similar effect was observed with BEZ235 at lower concentrations (Fig. 1A), suggesting that
mTORC1 may be more readily targeted than mTORC2. As with mTORC1, mTORC2
inhibition by BEZ235 was greatly enhanced by RAD001 (Fig. 1B). Moreover, from in vitro
studies, these effects appear to be elicited at the level of mTORC1 and mTORC2 (Fig. 2).
Although in HCC the major effects on proliferation appear to be through mTORC1, it is
clear in other tumor types, including phosphatase and tensin homolog deleted from
chromosome 10 (PTEN)–deficient prostate tumors, that the effects on tumor progression are
mTORC2- dependent (45). The therapeutic advantage of combining RAD001 with BEZ235
is that it should be efficacious in either tumor type. Moreover, because of the findings here
and those of Nyfeler et al. (41), one would predict that the rapamycins could be used in
combination with any mTOR ATP-binding site competitive inhibitor. Combination
treatment should decrease the effective dose of either drug, reducing off target effects of the
mTOR ATP-binding site competitive inhibitor.
We tested the efficacy of RAD001 and BEZ235 in HCC with the DEN mouse model, which
best represents human HCC with unfavorable outcome (21). Gene expression profiling
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showed that the major classes of genes affected in both mouse and human HCCs with poor
prognosis were cell proliferation and antiapoptotic genes (21). We find that DEN induced
HCCs treated with RAD001 and BEZ235 have a significant cell cycle inhibition signature.
Moreover, the drug combination, unlike either RAD001 or BEZ235 alone, revealed a
significant number of genes reverting to roughly baseline expression levels of normal livers,
suggesting that the effect of the two drugs together cannot be recapitulated by increasing the
dose of either drug alone. Recent data in ovarian cancer cells and non–small cell lung cancer
cells in culture and xenografts suggest that c-Myc is a major regulator of the tumor response
to rapamycin or RAD001 in combination with a PI3K/mTOR inhibitor (46, 47). However,
we found no evidence of significant alterations in genes transcriptionally regulated by c-
Myc in placebo- or drug-treated HCC DEN tumors. Our findings suggest that the
mechanisms at play may be unique to a syngeneic tumor confronted with an intact cytokine
and immune response arising from a natural history in the endogenous stroma or to HCC
itself, rather than cultured cell–initiated xenografts in immunocompromised mice.
It has been known for some time that inhibition of mTOR signaling in hepatocytes is
associated with the activation of autophagy (48). Moreover, recent studies describe the
spontaneous induction of liver adenomas in mice with a mosaic deletion of Atg5 or a liver
specific deletion of Atg7 (28). However, in other systems, autophagy supports tumor
persistence by maintaining cells under nutrient deprived conditions, thus acting as a survival
factor (49). In our hands, RAD001 and BEZ235 synergize at the level of autophagy as
shown by accumulation of the GST-BHMT fragment (Fig. 5). The increase in autophagy is
independent of 4E-BP1 and correlates with the dephosphorylation of ULK1 at S757, an
mTORC1 phosphorylation site (33). These findings suggest that activation of autophagy, in
a 4E-BP1/2/eIF-4G– independent manner, may be implicated in HCC regression observed in
tumors treated with combined RAD001/BEZ235 (Fig. 3). With the exception of Atg3, we
did not observe significant changes in the gene expression of autophagy genes in tumors
treated with the combination of RAD001 and BEZ235, compared to vehicle-treated tumors.
The significant autophagic response to mTOR inhibitors in the absence of major
transcriptional changes suggests that transcriptional reprogramming of autophagy genes was
not required for the mitophagy response. At this point, it will be important to determine the
extent to which the activation of mitophagy in DEN-induced HCCs contributes to tumor
regression.
RAD001 has been approved by the U.S. Food and Drug Administration for renal clear cell
carcinoma, TSC-associated subependymal giant cell astrocytoma, and neuroendocrine
tumors. However, in all cases, RAD001 delayed tumor progression, but there were no
complete responses. It may be that such effects are due to partial suppression of mTORC1
signaling by rapamycin derivatives, or resistant mechanisms may develop over time. The
combination of an ATP-binding site competitive mTOR inhibitor with a rapamycin
derivative may prove more effective in inhibiting additional targets of mTORC1. Our
hypothesis is that synergy may arise as a function of the ATP-competitive inhibitors having
enhanced access to the active site of the kinase. To our knowledge, there are no other
examples where two inhibitors act synergistically on the same target; thus, these studies
provide a strategy to increase the specificity of ATP-competitive inhibitors. On the basis of
our in vivo data, we have begun an investigator-initiated phase 1B-2 dose escalation study of
BEZ235 in combination with RAD001 in patients with HCC or other solid tumors. Since
rapamycin and its derivatives have already been approved clinically, their combination with
a PI3K/mTOR ATP-competitive inhibitor, such as BEZ235, would be a rapid strategy to test
the efficacy of this class of drugs in cancer and to fast-track their approval.
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Cell Culture and Proliferation assay
HEK293T cells purchased from the American Type Culture Collection and Huh7 cells from
Riken Cell Bank were maintained in Dulbecco’s modified Eagle’s medium (Hyclone)
containing 10% fetal bovine serum (Hyclone). Cell proliferation assays were performed with
the CellTiter-Glo Luminescent Cell Viability assay (Promega).
Animal Studies
C57BL/6 mice were obtained from the Jackson Laboratory. At 2 weeks, male mice were
injected intraperitoneally with DEN (50 mg/kg) (Sigma). At ~44 weeks, the animals (n = 9
to 10) were gavaged twice daily for 28 days with the specified doses of RAD001 and/or
BEZ235. The mice were starved for 3 hours before sacrifice and received their last dose of
RAD001 at the time of starvation and/or BEZ235 1 hour before sacrifice. Liver and tumor
tissues were immediately snap-frozen in liquid nitrogen for protein and RNA extraction or
fixed in 10% formalin for IHC analysis. Generation of the E2F1/c-Myc mice was previously
described (23). All in vivo studies were approved by the Institutional Animal Care and Use
Committee and performed following the ethical guidelines of the University of Cincinnati
and Cincinnati Children’s Hospital Medical Center.
Statistical Analyses
Data are presented as means ± SD unless otherwise specified. All the statistical analyses
were performed with GraphPad Prism 5. Unless otherwise specified in the figure legend,
statistical significance was determined with a one-way analysis of variance (ANOVA)
followed by a Bonferroni multiple group comparison test, with P values of <0.05, 0.001, and
0.0001 considered to be significant and represented with *, **, and ***, respectively.
Synergy was calculated with the ComboSyn Synergy software (version 3.0.1) on the basis of
the Chou-Talalay method (22).
Immunoblot analysis
Refer to Supplementary Materials.
In vitro mTOR kinase assays
Refer to Supplementary Materials.
Immunohistochemistry
Refer to Supplementary Materials.
BHMT assay
Refer to Supplementary Materials.
Magnetic resonance imaging
Refer to Supplementary Materials.
Microarray analyses
Refer to Supplementary Materials.
Electron microscopy
Refer to Supplementary Materials.
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Fig. S1. RAD001 and BEZ235 synergistically inhibit mTOR signaling in both human and
mouse HCC cell lines.
Fig. S2. RAD001 in combination with BEZ235 inhibits HCC progression better than the
single agents alone in DEN-injected mice.
Fig. S3. RAD001 and BEZ235 inhibit mTOR signaling in livers and tumors of DEN-
injected mice.
Fig. S4. RAD001 and BEZ235 treatment decreases HCC proliferation in E2F1/c-Myc mice.
Fig. S5. Kaplan-Meier plot grouped by gene expression of autophagy genes can predict
overall survival of HCC patients.
Table S1. Chou and Talalay calculation of synergy in RAD001- and/or BEZ235-treated
Huh7 cells.
Table S2. Renormalizing genes in RAD001- and/or BEZ235-treated tumors.
Table S3. Pairwise comparisons of differentially expressed pathways by GSEA in placebo-,
RAD001-, and/or BEZ235-treated tumors.
Table S4. Pairwise comparisons of autophagy-related genes between treatment groups.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Huh7 RAD001 and BEZ235 synergistically inhibit mTOR signaling and decrease
proliferation in Huh7 cells. Cells were treated with the indicated concentrations of RAD001
and/or BEZ235 for 48 hours. (A and B) Amounts of phosphorylated and total proteins were
measured in cell lysates by Western blot analysis. Actin was used as a loading control. (C)
Cell proliferation was measured using the CellTiter-Glo luminescent assay. The percent
change in cell number from the beginning of the treatment relative to vehicle is plotted.
Results are means ± SD (n = 3). ***P < 0.0001.
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RAD001 and BEZ235 synergistically inhibit the kinase activity of mTORC1 and mTORC2
in vitro. Endogenous mTORC1 or mTORC2 complexes were immunoprecipitated from
HEK293T cell lysates using a raptor or rictor antibody, respectively. (A and B) Kinase
activity was assayed for (A) mTORC1 or (B) mTORC2 using 4E-BP1 or Akt as substrates,
respectively. Each assay was performed a minimum of three times. A representative
Western blot analysis shows the amount of total and phosphorylated proteins in each
reaction. The graphs show the means ± SD (n = 3) of the amount of phosphorylated
substrate, minus the background level of the substrate alone, in each treatment. *P < 0.05;
**P = 0.001; ***P < 0.0001
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The combination of RAD001 and BEZ235 inhibits HCC progression better than the single
agents alone. Male C57BL/6 mice (n = 9 to 10) were injected with DEN at 2 weeks. After
44 weeks, mice were treated daily with placebo, RAD001, and/or BEZ235. (A) MRI scans
from days 0 and 28 of treatment are shown from a representative mouse from each group.
The percentage depicts the change in volume between the two time points. (B) Fold change
in tumor volume between days 0 and 28 based on quantification of the MRI scans. ***P <
0.0001, Kruskal-Wallis test followed by Dunn’s multiple comparisons test. (C)
Representative 100× magnification images of hematoxylin and eosin (H&E), Ki67, and
phospho–4E-BP1 (p-4E-BP1) T37/T46–stained tumor sections from mice from each of the
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treatment groups. (D and E) Percent proliferating cells (D) or p-4E-BP1 (E) per
preneoplastic focus or tumor based on quantification of immunohistochemical analysis of
paraffin-embedded tissue sections stained with Ki67 or p-4E-BP1 T37/T46 antibodies,
respectively. **P < 0.001; ***P < 0.0001, Mann-Whitney test.
Thomas et al. Page 16














RAD001 and BEZ235 cause reversal of gene expression levels in tumors. (A) Venn diagram
showing the numbers of genes reverting to expression levels equivalent to those of normal
liver in tumors treated with RAD001 and/or BEZ235. The numbers in parentheses show the
total number of genes in each treatment. (B) Heat map showing renormalizing genes
selected on the basis of a fourfold change in tumors treated with RAD001 and BEZ235
compared to placebo-treated tumors.
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The combination of RAD001 and BEZ235 synergistically affects autophagy independently
of 4E-BP1. (A and B) HEK293 cells stably expressing shNS (A) or sh4E-BP1/2 (B) were
transfected with GST-BHMT and treated 48 hours later with the indicated concentrations of
each drug for 6 hours. Cells were maintained in full medium or starved of serum and amino
acids for 6 hours as negative and positive controls for autophagy, respectively. The GST-
BHMT immunoprecipitates were analyzed by Western blot analysis to measure the indicated
proteins in each sample. GFPmyc is a control for plasmid expression level.
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Autophagosomes targeting mitochondria increase in numbers in tumors treated with
RAD001 and BEZ235 compared to tumors treated with placebo or either drug alone. (A)
Representative TEM images from one mouse per treatment show mitophagy (yellow arrows
point to forming autophagosomes). (B) Percent mitophagy was quantified by counting the
total number of mitochondria partially or fully engulfed with autophagosomes relative to the
total number of mitochondria counted per image. Results are means ± SD (n = 8 to 11). *P <
0.05; **P < 0.001.
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